Related Experiment Video

Updated: Jun 28, 2025

Murine Model of CD40-activation of B cells
12:24

Murine Model of CD40-activation of B cells

Published on: March 5, 2010

12.7K

Fcγ-Receptor-Independent Controlled Activation of CD40 Canonical Signaling by Novel Therapeutic Antibodies for Cancer

Karsten Beckmann1, Carmen Reitinger2, Xianglei Yan3,4

  • 1Biontech SE, Forstenrieder Str. 8-14, 82061 Neuried, Germany.

Antibodies (Basel, Switzerland)
|April 23, 2024
PubMed

Insights

New CD40 antibodies activate antigen-presenting cells independently of Fcγ-receptors (FcγR), offering a safer approach. These Fc-silenced antibodies show potent anti-tumor immune response activation without dose-limiting toxicities.

Area of Science:

  • Immunology
  • Oncology
  • Biotechnology

Background:

  • CD40-mediated signaling is crucial for anti-tumor immunity.
  • Current agonistic anti-CD40 antibodies often rely on Fcγ-receptor (FcγR) crosslinking for efficacy.
  • FcγR-dependent activation is associated with dose-limiting toxicities.

Purpose of the Study:

  • To identify novel anti-CD40 antibodies.
  • To develop Fc-silenced antibodies activating antigen-presenting cells (APCs) independently of FcγR.
  • To evaluate the efficacy and safety of these novel antibodies in preclinical models.

Main Methods:

  • Screening and characterization of Fc-silenced anti-CD40 antibodies.
  • Assessment of APC activation, including costimulatory receptor upregulation and cytokine release.
  • In vivo studies using humanized mouse models.

Main Results:

  • Identification of potent Fc-silenced anti-CD40 antibodies.
  • Demonstrated FcγR-independent activation of APCs, including dendritic cells.
  • Effective upregulation of costimulatory molecules and cytokine production.
  • Preclinical efficacy and lack of toxicity observed in humanized mice.

Conclusions:

  • Fc-silenced anti-CD40 antibodies can potently activate APCs without FcγR engagement.
  • These antibodies offer a promising therapeutic strategy for cancer immunotherapy.
  • Potential for safe and efficacious combination therapies in cancer patients.
Keywords:
CD40antibodydendritic cellimmune cell activationimmunoglobulin

More Related Videos

Generation of Human CD40-activated B cells13:27

Generation of Human CD40-activated B cells

Published on: October 16, 2009

15.3K
Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

3.5K

Related Concept Videos

T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
714
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
520
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
134